RecruitingPHASE1, PHASE2NCT05039281

Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma

Studying Gliosarcoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
M.D. Anderson Cancer Center
Principal Investigator
Shiao-Pei S Weathers, M.D
M.D. Anderson Cancer Center
Intervention
Atezolizumab(biological)
Enrollment
6 enrolled
Eligibility
18 years · All sexes
Timeline
20222027

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05039281 on ClinicalTrials.gov

Other trials for Gliosarcoma

Additional recruiting or active studies for the same condition.

See all trials for Gliosarcoma

← Back to all trials